Get the latest insights on the Indian stock market, including the trade setup for Nifty and Sensex, key support and resistance levels, and expert analysis for investors and traders.
Infosys management’s positive outlook on FY26 growth, driven by robust AI segment, data, and cloud deals, amidst an uncertain business environment.
Infosys Ltd. reported a steady start to fiscal 2026, with revenue rising 3.3% quarter-on-quarter to Rs 42,279 crore, ahead of estimates. The company delivered a strong operational performance and continued its focus on disciplined cash management.
Tata Consumer Products Ltd. expects its branded tea margins to bounce back by the December quarter, aided by lower auction prices and improved pass-through of cost inflation.
Global macro hedge fund Discovery Capital Management has exited SpiceJet by selling its entire 2.2% stake in the domestic carrier for Rs 119 crore. Explore the key takeaways and market implications of this deal.
More than 60 companies, including Canara Bank, Bajaj Finance, SBI Life, and Nestle India, are set to announce their quarterly earnings for the April-June period.
Kajaria Ceramics Ltd. has received mixed reviews from brokerages post its Q1 review. UBS has upgraded its rating to ‘buy’ while Jefferies has downgraded its rating to ‘hold’. We dive deep into the reasons behind these contrasting views.
Read the latest Infosys Q1 results review by Motilal Oswal, including their views on the company’s guidance, discretionary spending, and near-term catalysts.
Dr. Reddy’s Laboratories Ltd.’s Q1 FY26 results were below estimates due to weaker-than-expected performance in North America, led by price erosion and lower offtake for gRevlimid.
Eris Lifesciences Ltd. is set to enter an execution phase after multiple merger and acquisitions over FY23–25, with an investment of Rs 38–40 billion to create multiple levers of growth. Read on to know more about the company’s growth strategy and its impact on the stock.